Ana Chadwick serves as Chief Financial Officer and Treasurer at Insulet Corporation, a pioneering medical technology company renowned for its Omnipod insulin management system. With over 20 years of experience in finance and strategic leadership within the healthcare and technology sectors, Ana joined Insulet in 2018, bringing a proven track record of driving financial excellence and operational growth. She holds a Bachelor of Science in Accounting from the University of California, Berkeley, and an MBA from Harvard Business School, where she honed her expertise in corporate finance and mergers and acquisitions. Prior to Insulet, Ana held senior finance roles at Medtronic, where she spearheaded global treasury operations and contributed to a $4.2 billion acquisition that expanded the company's diabetes care portfolio. Her achievements include optimizing capital structures to reduce debt by 30% during economic downturns and implementing enterprise-wide ERP systems that enhanced forecasting accuracy by 25%. At Insulet, Ana has been instrumental in supporting the company's revenue growth from $1 billion to over $1.7 billion annually, while navigating complex regulatory landscapes and securing strategic funding for R&D innovations. In her current role, Ana oversees all financial planning, reporting, treasury functions, and investor relations, ensuring fiscal discipline amid rapid expansion in the connected health ecosystem. Her strategic vision has positioned Insulet for sustainable profitability, earning her recognition as a top CFO in MedTech by Forbes in 2023. Ana is a passionate advocate for diversity in STEM finance and serves on the board of the Healthcare Financial Management Association.